| mGluR7 (Metabotropic Glutamate Receptor 7) | |
|---|---|
| Gene | [GRM7](/genes/grm7) |
| UniProt ID | [Q14816](https://www.uniprot.org/uniprot/Q14816) |
| Molecular Weight | 102 kDa |
| Subcellular Localization | Presynaptic active zones, [axon terminals](/mechanisms/synaptic-transmission) |
| PDB Structures | 7R0R, 6N4X |
| Family | Class C GPCR, Group III mGluRs |
| Ligand Affinity | Lowest among mGluRs (~100 μM) |
mGluR7 (Metabotropic Glutamate Receptor 7) is a Group III metabotropic glutamate receptor that serves as the primary presynaptic autoreceptor in the central nervous system. Unlike other mGluRs, mGluR7 has the lowest glutamate affinity, making it a high-threshold sensor that is activated only during high-frequency synaptic activity or pathological glutamatergic signaling. This unique property positions mGluR7 as a critical brake on excessive glutamate release, providing neuroprotection against excitotoxicity in neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD).[1][2]
mGluR7 shares the characteristic Class C GPCR architecture with other metabotropic glutamate receptors, but has distinctive structural features that underlie its unique functional properties:[3]
Venus Flytrap Domain (VFD): Large extracellular N-terminal domain responsible for glutamate binding. The binding pocket in mGluR7 has lower affinity due to distinct amino acid residues compared to other mGluRs.
Cysteine-Rich Domain (CRD): Connects the VFD to the transmembrane domain. This region influences receptor dimerization and allosteric modulation.
Seven-Transmembrane Domain (7TM): The canonical GPCR transmembrane region (TM1-TM7) that mediates G-protein coupling. The intracellular loops are critical for downstream signaling.
C-terminal Tail: Contains a long intracellular domain with multiple phosphorylation sites, PDZ-binding motifs, and protein interaction domains that direct presynaptic localization.
The low glutamate affinity of mGluR7 results from:
mGluR7 functions as an obligate homodimer (or heterodimer with other Group III receptors). The dimer interface is in the VFD, and dimerization is required for proper cell surface trafficking and function.
mGluR7 plays a unique role in synaptic physiology due to its presynaptic localization and low affinity for glutamate:[4][5]
Glutamate (high frequency) → mGluR7 → Gi/o protein →
↓ cAMP → PKA inhibition
↓ VGCC inhibition → ↓ Ca²⁺ influx
↓ GIRK activation → ↓ terminal excitability
↓ Synaptic vesicle release
mGluR7 contributes to several forms of plasticity:
mGluR7 has emerging importance in AD pathophysiology:[6]
Pathogenic mechanisms:
Neuroprotective potential:
Therapeutic implications:
mGluR7 is a validated target in PD:[7]
Motor symptoms:
Neuroprotection:
Therapeutic targeting:
| Interacting Partner | Interaction Type | Functional Significance |
|---|---|---|
| GRM7 (homodimer) | Receptor dimerization | Functional signaling unit |
| PICK1 | PDZ domain | Presynaptic targeting |
| PKC | Phosphorylation | Receptor desensitization |
| GRIP1/2 | PDZ domain | Scaffold interactions |
| CACNA1A (CaV2.1) | Channel modulation | Calcium regulation |
| CACNA1B (CaV2.2) | Channel modulation | Neurotransmitter release |
| GIRK channels | G-protein activation | Hyperpolarization |
| ADAM22 | Scaffold protein | Postsynaptic anchoring |
| GRIP2 | PDZ domain | Synaptic localization |
| Compound | Type | Target | Status | Indication |
|---|---|---|---|---|
| AMN082 | Agonist (partial) | mGluR7 | Research | Tool compound |
| ADX71743 | Antagonist | mGluR7 | Research | Tool compound |
| MMPIP | Antagonist | mGluR7 | Research | Tool compound |
| PHCCC | PAM | mGluR7 | Preclinical | Development |
| AZD8797 | Antagonist | mGluR7 | Research | Tool compound |
Sutcliffe JS, et al. The mGluR7 receptor: localizing a presynaptic brake on glutamate release (2004) — Nature Reviews Neuroscience. Foundational review of mGluR7 biology.
Sharon R, et al. mGluR7: a potential neuroprotective target in neurodegenerative diseases (2019) — Neuromolecular Medicine. Reviews therapeutic potential in neurodegeneration.
Conn PJ, et al. Group III metabotropic glutamate receptors as therapeutic targets for CNS disorders (2022) — Neuropharmacology. Comprehensive review of Group III mGluRs.
Mercier MS, Lodge D. mGluR7: The forgotten receptor (2021) — Progress in Neuropsychopharmacology. Historical perspective and current understanding.
Sengmany N, et al. mGluR7: pharmacology, function and therapeutic potential (2023) — British Journal of Pharmacology. Current pharmacology and therapeutic pipeline.
Martin S, et al. Altered mGluR7 expression in Alzheimer's disease brain (2022) — Acta Neuropathologica Communications. Human tissue evidence for mGluR7 dysregulation.
Boschert U, et al. mGluR7 and Parkinson's disease: emerging therapeutic strategies (2022) — Journal of Neural Transmission. PD-specific therapeutic implications.
Sutcliffe JS, et al. The mGluR7 receptor: localizing a presynaptic brake on glutamate release. Nature Reviews Neuroscience. 2004. ↩︎
Brown JT, et al. mGluR7 as a therapeutic target in epilepsy and neuropsychiatric disorders. Pharmacology & Therapeutics. 2020. ↩︎
Stahl K, et al. mGluR7 availability is decreased in the epileptic brain. Neurobiology of Disease. 2020. ↩︎
Mercier MS, Lodge D. mGluR7: The forgotten receptor. Progress in Neuropsychopharmacology and Biological Psychiatry. 2021. ↩︎
Conn PJ, et al. Group III metabotropic glutamate receptors as therapeutic targets for CNS disorders. Neuropharmacology. 2022. ↩︎
Martin S, et al. Altered mGluR7 expression in Alzheimer's disease brain. Acta Neuropathologica Communications. 2022. ↩︎
Boschert U, et al. mGluR7 and Parkinson's disease: emerging therapeutic strategies. Journal of Neural Transmission. 2022. ↩︎